Akademik Veri Yönetim Sistemi
Turkiye Klinikleri Journal of Medical Sciences, cilt.37, sa.4, ss.191-200, 2017 (SCI-Expanded)
© 2017 by Türkiye Klinikleri.Cancer is a major human health problem and one of the principal reasons of morbidity and mortality in both developing and industrialized countries. Cancer is the second leading cause of death worldwide and globally nearly 1 in 6 deaths is due to cancer. Colorectal cancer is third most common cancer and the fourth most common cause of cancer-related death, with 700.000 deaths per year. By gender, colorectal cancer is the second most common cancer in women (9.2%) and the third in men (10%). The incidence of colorectal cancer has risen by 200.000 new cases per year from 1990 to 2012. Most cases of colorectal cancer are detected in Western countries (55%). Early detection of colorectal cancer is important for treatment. It has been observed that morbidity and mortality due to colorectal cancer can be reduced by screening programs. Surgical intervention, chemotherapeutics such as 5-fluorouracil (5-FU), irinotecan, capecitabine, oxaliplatin and monoclonal antibodies like cetuximab, bevacizumab, panitumumab are used for treatment. The combination of “Trifluridine/tipiracil” 15 and 20 mg tablets, is a new antineoplastic agent. “Trifluridine/ tipiracil” is comprised of an antineoplastic thymidine-based nucleoside analogue, trifluridine, and the thymidine phosphorylase (TPase) inhibitor, tipiracil. It is a new oral fluoropyrimidine treatment approved by United States, Europe and Japan for treatment of metastatic colorectal cancer. By this research, it is aimed to survey the structure, synthesis and the biological activity of “trifluridine and tipiracil” which a new combination for using against metastatic colorectal cancer.